Metraipolis › archive › dc_bfba28a04e65

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir-based antiretroviral therapy — Europe PMC PMID:41622121

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41622121
DOI
10.1111/hiv.70204
License (as archived)
solo-consultazione
Archived
2026-11-06T08:18:25.003Z
SHA-256 of the archived text
b7767a46a620b2dfa9bd5c93e81f2f3dedae9e6111fac6f24c164091507d8416
Stable URL of this page
https://metraipolis.com/documento/dc_bfba28a04e65

How to cite

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir-based antiretroviral therapy — Europe PMC PMID:41622121 — Europe PMC (en), https://europepmc.org/article/MED/41622121 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bfba28a04e65 (Metraipolis archive dc_bfba28a04e65, sha256 b7767a46a620b2dfa9bd5c93e81f2f3dedae9e6111fac6f24c164091507d8416)
BibTeX
@misc{dcbfba28a04e65,
  title = {Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir-based antiretroviral therapy — Europe PMC PMID:41622121},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41622121},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bfba28a04e65; sha256 b7767a46a620b2dfa9bd5c93e81f2f3dedae9e6111fac6f24c164091507d8416},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41622121. Agents can read the archived copy with the MCP tool read_document.